Bevacizumab Biosimilar Exporter and Supplier from India
You are sourcing a recombinant anti-VEGF monoclonal antibody that has to arrive at 2-8C with its cold chain intact and its dossier ready for your regulator. M Care Exports is a Mumbai-based merchant-exporter trading pharmaceuticals since 2003, supplying bevacizumab biosimilar 100mg/4mL and 400mg/16mL vials drawn from WHO-GMP-listed Indian manufacturing lines. We are not the manufacturer: we consolidate, cold-ship and paper the consignment so your import clears on the first attempt.
Bevacizumab biosimilar in export volumes for tenders and distributors
Bevacizumab is a biological, not a small-molecule generic, and that changes how it is sourced. Every vial you buy from us is a biosimilar referenced to the originator, released by an Indian manufacturer and moved under an unbroken 2-8C chain. We work with importers, oncology distributors and hospital or government tender buyers who need documented provenance, a manufacturer batch-release trail and validated temperature logging rather than a spot-market pallet of uncertain origin.
Biosimilar, stated plainly
What we supply is a biosimilar of bevacizumab, not the reference brand. We do not claim automatic interchangeability with the originator: substitution and interchangeability are decisions for your national regulator and prescriber, and we frame the product honestly on every quotation.
Cold chain is the whole job
2-8C throughout, never frozen, never shaken. We ship in qualified insulated shippers with data-logging temperature monitors so your receiving pharmacy can verify the chain held from our floor to your cold room.
Two vial presentations
100mg/4mL and 400mg/16mL single-use vials at 25 mg/mL. The 400mg vial reduces per-mg handling for high-throughput oncology day-units; the 100mg suits smaller dosing schedules and lower-volume clinics.
Sourced from WHO-GMP lines
We supply from WHO-GMP-listed manufacturing sites in India. The GMP and any WHO-PQ status belong to the manufacturer, not to M Care. Our own credential is ISO 9001:2015 as a trading and export house.
Bevacizumab at a glance: form, strength and regulatory class
Active ingredient
Bevacizumab, a recombinant humanised IgG1 monoclonal antibody that binds vascular endothelial growth factor A (VEGF-A) and blocks tumour angiogenesis.
Strengths stocked
100mg/4mL and 400mg/16mL single-use vials, concentrate for solution for infusion at 25 mg/mL, for dilution in 0.9% sodium chloride before intravenous infusion.
Formulation and handling
Clear to slightly opalescent sterile liquid concentrate. Store 2-8C in the outer carton, protected from light. Do not freeze and do not shake. Diluted infusion should be used promptly per the manufacturer's leaflet.
Regulatory class
Prescription-only biological (anti-neoplastic monoclonal antibody). ATC code L01FG01. Supplied as a biosimilar, not the reference product.
Therapeutic area
Oncology, anti-angiogenic. Used across colorectal, lung, renal, glioblastoma and gynaecological indications, with widespread off-label intravitreal ophthalmic use.
Reference brands (buyer context only)
Importers commonly cross-reference the originator Avastin and Indian biosimilars such as Advamab, Cizumab, Bevacirel, Bryxta and Abevmy. Named for identification, not as retail offers.
The buyers we quote bevacizumab biosimilar to
Bevacizumab demand in export markets sits with buyers who can hold a cold chain and satisfy an oncology-grade dossier. These are the segments that come to us.
Oncology-focused importers and distributors
Companies building a biosimilar oncology portfolio across GCC, Africa, Latin America and South-East Asia who want a documented Indian source and a partner that understands cold-chain freight, not just carton counts.
Hospital and government tender buyers
Public oncology programmes and tender agents needing CTD-ready documentation, a CoPP and a consistent manufacturer trail to qualify a biosimilar line against an originator reference.
Regional wholesalers seeking a stable second source
Buyers who tell us they need a partner for a molecule where supply and price of the originator have squeezed their margins, and want a biosimilar alternative they can defend on provenance.
Re-exporters and consolidators
Trade houses assembling multi-line oncology shipments who value a single Indian consolidator that can add trastuzumab and rituximab biosimilars to the same documented consignment.
Safety-critical warnings your clinical teams already know
This section is reference context for professional buyers and their clinical teams, not medical advice or a dosing instruction to any patient. Bevacizumab carries serious labelled warnings that shape how it is used. The most significant are gastrointestinal perforation, serious or fatal haemorrhage including haemoptysis, and wound-healing complications, for which treatment is typically withheld for a defined interval before and after elective surgery. These are boxed-warning class events in most reference labels.
Further recognised risks include hypertension, proteinuria and nephrotic syndrome, arterial and venous thromboembolism, congestive heart failure, and posterior reversible encephalopathy syndrome (PRES). Infusion reactions can occur. Dosing is weight-based and indication-specific (commonly cited in the 5 to 15 mg/kg range at 2 to 3 week intervals depending on the regimen), shown here only as context; the manufacturer's approved prescribing information and the treating oncologist govern actual use.
Because this is a biosimilar, we do not represent it as automatically interchangeable with the originator. Pharmacovigilance, batch traceability and any substitution decision remain matters for your regulator, importer of record and prescriber.
Written for professional buyers and importers, not as medical advice. Prescribing decisions sit with the treating clinician and the approved label in your market.
Export and registration documents we compile with you
A biosimilar oncology import stands or falls on its paperwork. Here is what M Care genuinely provides or coordinates alongside the manufacturer for a bevacizumab consignment.
CTD dossier support
We compile and collate the CTD dossier with you, drawing the module content from the source manufacturer, so your regulatory affairs team files a complete submission rather than chasing scattered documents.
CoPP and free-sale coordination
We coordinate the Certificate of Pharmaceutical Product and free-sale documentation from the manufacturing source to support your national registration.
Manufacturer GMP evidence
WHO-GMP certificates and site licences of the manufacturing line, provided as the manufacturer's credentials. M Care does not hold GMP or WHO-PQ itself.
Batch and cold-chain records
Certificate of Analysis, batch-release documents and temperature data-logger records for each shipment, so the receiving pharmacy can confirm the 2-8C chain was maintained.
Shipping and customs pack
Commercial invoice, packing list, cold-chain airway documentation and country-specific import annexes prepared for clean customs clearance.
Molecules buyers source alongside Bevacizumab (Biosimilar).
How ordering works.
- Send your enquiry Tell us the presentation (100mg/4mL, 400mg/16mL or both), destination market, target quantity and whether the volume is for a tender, registration batch or ongoing distribution.
- Receive a documented quotation We confirm the manufacturing source, current availability, lead time and a price on request, along with the batch-release minimum set by the source manufacturer rather than any invented MOQ.
- Align the dossier and cold-chain plan We agree the CTD, CoPP and CoA package and the qualified cold-chain freight route, and share sample documentation for your regulatory review before despatch.
- Cold-ship and track The consignment moves under monitored 2-8C conditions with data loggers, and we hand over the full shipping and quality pack on arrival.
Bevacizumab (Biosimilar) supply, the specific questions.
Is the bevacizumab you supply the original Avastin or a biosimilar?
We supply a biosimilar of bevacizumab from Indian manufacturing lines, not the originator Avastin. Reference brands are named only so you can identify the molecule and its comparator. Where a specific source or brand matters for your registration, tell us and we quote against it transparently.
Is a bevacizumab biosimilar interchangeable with the reference product?
Interchangeability and substitution are decisions for your national regulator and the treating prescriber, not something a supplier can assert. We do not claim automatic interchangeability. We provide the manufacturer's comparability and quality documentation so your regulatory team can make that determination.
How do you protect the cold chain in transit?
Bevacizumab ships at 2-8C, never frozen and never shaken. We use qualified insulated shippers with electronic temperature data loggers, and hand over the logger records with each consignment so your receiving pharmacy can verify the chain held end to end.
What is the minimum order quantity?
There is no fixed catalogue MOQ. The practical minimum is set by the source manufacturer's batch-release minimum for a biological, which we confirm on your specific enquiry along with lead time and price on request.
Which strengths and pack sizes can you export?
We supply the 100mg/4mL and 400mg/16mL single-use vials, both concentrate for solution for infusion at 25 mg/mL. Tell us your split across the two and we confirm availability from the current manufacturing source.
Can you support product registration in our market?
Yes. We compile the CTD dossier alongside you and coordinate the CoPP, CoA and manufacturer GMP evidence from the source. The GMP and any WHO-PQ status are the manufacturer's; our own credential is ISO 9001:2015 as an export house.
Do you supply bevacizumab for ophthalmic (intravitreal) use?
Intravitreal use in wet AMD and diabetic macular oedema is a widely practised but off-label application, not a labelled indication of the standard oncology vial. We can supply the same vials, but the off-label decision and any compounding rest entirely with the prescriber and your regulator. We do not market it as an approved eye treatment.
Request a bevacizumab biosimilar quotation
Send us your destination market, the vial split across 100mg/4mL and 400mg/16mL, and your target volume. We reply with the manufacturing source, lead time, cold-chain plan, dossier support and a price on request. All shipments move under monitored 2-8C conditions from WHO-GMP-listed Indian lines.